Global Small Molecule CDMO Industry Research Report 2023

DUBLIN, Aug. 4, 2023 /PRNewswire/ — The “Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Market Growth Opportunities, 2023” report has been added to ResearchAndMarkets.com’s offering.

This report overviews the global small-molecule CDMO market. The study period is 2021-2028, with 2022 as the base year and 2023-2028 as the forecast period.

We segment the study into two main categories based on the product type: active pharmaceutical ingredients (API)/drug substance manufacturing and fixed dosage form (FDF)/drug product manufacturing. The publisher segments API further into innovator and generic and FDF into oral, semisolid/liquid, and injectables.

CDMOs are third-party vendors that offer outsourced development and manufacturing services for pharmaceutical drugs. In the small molecule manufacturing sector, CDMOs provide expert development and manufacturing services and are now an essential part of the pharmaceutical industry’s value chain.

The growing incidence of chronic diseases propels the demand for innovative small-molecule medicines. The pharmaceutical industry’s focus on developing novel, more efficacious, and targeted therapies has resulted in increased product pipelines and the need for innovative drug delivery methods. Simultaneously, while small and mid-sized pharma companies are responsible for over 70% of drugs in the R&D pipeline, they often lack the expertise to bring their clinical pipeline to market.

The publisher expects sustained growth during the forecast period, driven by increasing demand for small molecules in oral solid formulations, targeted drug delivery technologies, potent and highly potent drugs, and other complex molecules. CDMOs equipped to provide technological leadership, flexibility, expertise for modular manufacturing, end-to-end capabilities and capacities, and innovative drug delivery technologies will likely emerge as the partner of choice.

To drive growth, CDMOs will continue prioritizing innovation, collaboration, expansion, automation, and optimization across all aspects of the manufacturing process. Most importantly, the report highlights opportunities for participants of all sizes based on the evolving needs and innovations in the small-molecule CDMO market, the emergence of targeted therapeutics, highly potent APIs, and complex drugs.

RESEARCH HIGHLIGHTS

Revenue forecasts by segment and region (North America, Europe, Asia-Pacific, and the Rest of the World)
Market share of leading participants, consolidation and expansion initiatives, and developments in service offerings and business models
Factors influencing CDMO selection
CDMOs’ focus on sustainability and flexible manufacturing expertise

Growth Opportunity Universe

BA Enhancement Solutions for OSD Formulation
Radiopharmaceutical Manufacturing for Targeted Therapeutics
Innovative and Connected Packaging Solutions for Serialization
Differentiated Capabilities for Injectable Specialty Generics

Key Topics Covered:

1 Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative
The Impact of the Top 3 Strategic Imperatives on the Global Small Molecule CDMO Industry
Growth Opportunities Fuel the Growth Pipeline Engine

2 Growth Opportunity Analysis

Scope of Analysis
Segmentation by Product Type
Segmentation by Service Type
Key Competitors
Growth Metrics
Growth Drivers
Growth Restraints
Forecast Framework: Market Sizing
Forecast Methodology
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region
Revenue Forecast by Product Type
Revenue Forecast Analysis by Product Type
Revenue Share Forecast by Service Type
Revenue Share Forecast Analysis by Service Type
Competitive Environment
Revenue Share
Revenue Share Analysis

3 Growth Environment

Comparison Between Small Molecules and Biologics Approvals
Small Molecule Market Outlook: Main Therapy Area and Dosage Form
Growing Pipeline and Product Innovation
Building Expertise in HPAPI Enabling Precision Medicine
Expanding the CDMO Value Chain: Transition to a CRDMO Model
Expanding the CDMO Value Chain: Comprehensive End-to-end Offering
Initiatives Supporting Transition to the CRDMO Model
Capability Evolution for Transitioning the Business Model from Project-based to Integrated Long-term
Factors Influencing CDMO Selection
Factors Influencing CDMO Selection: Analysis
ESG-focused Initiatives to Become a Partner-of-Choice
Consolidation Steps in the Small Molecule CDMO Industry
Expansion Initiatives to Capitalize on Scale and Broadening Portfolio
Summary of Growth Trends Shaping the Small Molecule CDMO Industry

4 Growth Opportunity Analysis: API

Growth Metrics
Revenue Forecast
Revenue Forecast by Product Type
Forecast Analysis

5 Growth Opportunity Analysis: FDF

Growth Metrics
Revenue Forecast
Revenue Forecast by Product Type
Forecast Analysis: Oral
Forecast Analysis: Injectable
Forecast Analysis: Liquids/Semisolids
Forecast Analysis: Others

For more information about this report visit https://www.researchandmarkets.com/r/7mqesx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716